KDA Group has signed an exclusive letter of intent to acquire tu ZRx prescriber technology asset for development and operation in the United States and Europe

18 November 2020

Thetford Mines, Quebec – November 18, 2020 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the Corporation has signed an exclusive Letter of Intent (the “LOI”) with ZoomMed Medical Inc. (“ZoomMed Medical”) for the acquisition of the ZRx Prescriber technology asset consisting of its platform and source codes (the “ZRx Prescriber Asset”). KDA aims to develop and use the ZRx Prescriber Asset in the United States and Europe.